Survey of Practices Regarding the Use of Taurolidine Lock Solutions in Patients With Insertion of a Peripherally Inserted Central Catheter (PICC) in a Vascular Access Unit (TAURO-USE2)

November 26, 2025 updated by: University Hospital, Grenoble

The primary objective of this study is to describe current practices regarding the administration of taurolidine lock solutions in relation to medical prescriptions for patients who have undergone peripherally inserted central catheter (PICC) implantation in the Vascular Access Unit as part of parenteral nutrition therapy. Our underlying hypothesis is that the use of taurolidine lock solutions may deviate from current recommendations, particularly with respect to administration procedures.

This study will allow us to characterize the use of taurolidine lock solutions in relation to medical prescriptions, identify potential deviations from recommended practices, and document any associated adverse events. It will also enable follow-up of PICC outcomes at 8 and 30 days after implantation in the Vascular Access Unit, whereas current follow-up is performed only at 8 days post-insertion.

Study Overview

Status

Not yet recruiting

Conditions

Taurolidine Lock Solution

Study Type

Observational

Enrollment (Estimated)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Cordélia SALOMEZ-IHL, pharmacist
Phone Number: + 33 (0)4 76 76 85 27
Email: cihl@chu-grenoble.fr

Study Contact Backup

Name: Aida MANDZO, clinical research associate
Phone Number: +33 (0)4 76 76 68 16
Email: amandzo@chu-grenoble.fr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Adult
Older Adult

Accepts Healthy Volunteers

Sampling Method

Non-Probability Sample

Study Population

All patients meeting the inclusion criteria will be recruited consecutively over a three-month period to minimize the risk of selection bias.

Description

Inclusion Criteria:

Patient who has undergone PICC placement in the vascular access unit with an indication for parenteral nutrition supplementation.
Patient not opposed to participating in this research.

Exclusion Criteria:

Patient not speaking French
Patient under guardianship or conservatorship
Patient with major neurocognitive disorders
Patient with severe hearing impairment
Patient who do not have a telephone

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To characterize, through an assessment of current practices, the administration of taurolidine lock solutions as prescribed for patients who have undergone PICC implantation in the Vascular Access Unit as part of parenteral nutrition therapy. Time Frame: Eight and thirty days after PICC placement in the Vascular Access Unit	Proportion of patients with a prescription for a taurolidine lock solution who actually receive administrations of the prescribed lock solution (concordance between prescribed and administered product). Proportion of patients for whom lock solutions are administered in accordance with the manufacturer's instructions for use; compliant administration is defined as the nurse performing all recommended steps for applying the lock solution at the end of each parenteral nutrition infusion. Proportion of patients for whom lock solutions are withdrawn in accordance with the manufacturer's instructions for use (lock solutions aspirated before catheter use). Proportion of patients for whom lock solutions are disposed of in accordance with regulations for biological-hazard waste.	Eight and thirty days after PICC placement in the Vascular Access Unit

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Describe nurses' perceptions of their own knowledge regarding the use of taurolidine lock solutions. Time Frame: Eight and thirty days after PICC placement in the Vascular Access Unit.	Quantify, using a self-assigned score, nurses' level of knowledge concerning taurolidine lock solutions. Proportion of nurses aware of the various properties of lock solutions according to the references available on the market.	Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the medical care provided by home service providers for patients receiving a PICC placement for parenteral nutrition supplementation. Time Frame: Eight and thirty days after PICC placement in the Vascular Access Unit.	Nature and number of service providers working with patients at home.	Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the supply chain for taurolidine lock solutions. Time Frame: Eight and thirty days after PICC placement in the Vascular Access Unit.	Nature and proportions of procurement methods for taurolidine lock solutions for patients at home.	Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the elements related to PICC placement. Time Frame: Eight and thirty days after PICC placement in the Vascular Access Unit.	Nature and proportions of elements related to PICC placement: number of lumens, vein of insertion, side of insertion, duration of placement, and role of the inserter (nurse anesthetists or physician).	Eight and thirty days after PICC placement in the Vascular Access Unit.
Characterize the functional status of the PICC over time. Time Frame: Eight and thirty days after PICC placement in the Vascular Access Unit.	Proportion of PICC in place and functional at 8 and 30 days post-insertion, defined as not requiring premature removal and allowing infusion and blood sampling.	Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe complications related to PICC placement. Time Frame: Eight and thirty days after PICC placement in the Vascular Access Unit.	Nature and proportions of complications related to the PICC occurring within 8 and 30 days post-insertion.	Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the causes of premature PICC removal. Time Frame: Eight and thirty days after PICC placement in the Vascular Access Unit.	Nature and proportions of causes for premature PICC-line removal within 8 and 30 days post-insertion.	Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe adverse events related to the use of taurolidine lock solutions. Time Frame: Eight and thirty days after PICC placement in the Vascular Access Unit.	Nature and proportion of adverse events potentially related to the use of a taurolidine lock solution, as reported by patients or healthcare providers.	Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the difficulties encountered by healthcare professionals when using taurolidine lock solutions. Time Frame: Eight and thirty days after PICC placement in the Vascular Access Unit.	Nature and proportion of difficulties encountered by home-care nurses when using taurolidine lock solutions.	Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the information sources used by healthcare professionals regarding taurolidine lock solutions. Time Frame: Eight and thirty days after PICC placement in the Vascular Access Unit.	Nature and proportion of information sources consulted by nurses in the event of problems related to the use of a taurolidine lock solution or to the use of the PICC.	Eight and thirty days after PICC placement in the Vascular Access Unit.
Characterize the use of device vigilance in the event of adverse events related to taurolidine lock solutions. Time Frame: Eight and thirty days after PICC placement in the Vascular Access Unit.	Proportion of nurses who would report to device vigilance any adverse events related to the use of a taurolidine lock solution or to the use of the PICC, should such events occur.	Eight and thirty days after PICC placement in the Vascular Access Unit.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Grenoble

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2025

Primary Completion (Estimated)

March 1, 2026

Study Completion (Estimated)

March 1, 2026

Study Registration Dates

First Submitted

November 17, 2025

First Submitted That Met QC Criteria

November 26, 2025

First Posted (Actual)

December 2, 2025

Study Record Updates

Last Update Posted (Actual)